In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...
Read MoreCurrently pregnant or breastfeeding-Neither Posts on Medivizor
Searching for patients with unresponsive chronic lymphocytic leukemia to trial an experimental treatment.
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....
Read MoreSearching for patients with solid tumors with abnormal genetic changes to trial an experimental medication
In a nutshell This study is searching for participants with advanced solid tumors including breast cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read MoreSearching for patients with metastatic breast cancer to trial a targeted therapy
In a nutshell This phase 2 clinical trial is evaluating the safety and effectiveness of targeted therapy TAS-120 (futibatinib) alone or in combination with fulvestrant (Faslodex) in patients with metastatic breast cancer (mBC). The main outcomes to be evaluated will be the response rate and survival without cancer worsening. The details Breast...
Read MoreTreating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor
In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...
Read MoreLooking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.
In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...
Read MoreSeeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read MoreSeeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read MoreSeeking patients with relapsed follicular lymphoma for dosing study of idelalisib
In a nutshell This study will evaluate the best dose of idelalisib (Zydelig) for patients with relapsed follicular lymphoma (FL). The primary outcomes are overall response and side effects. The details FL is a slow-growing cancer of B-cells, a type of white blood cell. Idelalisib is a medication that inhibits certain proteins involved in...
Read MoreSearching for patients with advanced triple-negative breast cancer to trial a treatment combination
In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...
Read MoreSearching for patients with rheumatoid arthritis to switch to a rituximab biosimilar
In a nutshell This phase 3 trial will investigate the safety and effectiveness of switching from rituximab (Rituxan/Mabthera) to DRL_RI in patients with rheumatoid arthritis (RA). The main outcome will be the rate of side effects and anti-drug drug antibodies (ADAs). This study is recruiting at several locations in the United...
Read MoreLooking for patients with AML to try a combination treatment
In a nutshell This trial is evaluating the effectiveness of KRT-232 for the treatment of acute myeloid leukemia (AML). The main outcomes are the number of patients who achieve complete remission, and how many patients stop treatment due to side effects. This study is being conducted in Columbus, Ohio, United States. The details AML is a...
Read More